Nektar Therapeutics | NKTR - 销售毛利



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 10.87B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


销售毛利 更改 日
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
ALKERMES USD 331.33M 7M 2026-03
Amgen USD 6.89B 415M 2025-12
Baxter International USD 891M 314M 2026-03
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cipla INR 39.1B 2.54B 2026-03
Dr.Reddys Laboratories INR 37.77B 13.6B 2026-03
Eisai JPY 153.41B 15.44B 2026-03
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Exelixis USD 590.86M 18.68M 2026-03
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 10.85B 2.57B 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Takeda JPY 688.84B 101.71B 2026-03
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Xencor USD 21M 22.61M 2025-09